Ph1 Lobeline Interaction Study - 1

Phase 1

• Conditions: Methamphetamine Dependence

• Registration Number: NCT00439504
• Lead Sponsor: National Institute on Drug Abuse (NIDA)

Brief Summary

The purpose of this study is to determine if there are significant cardiovascular or other interactions between sublingual lobeline and intravenous methamphetamine.

Detailed Description

Not available

Study Timeline

• Status Verified: 2007-02
• Study First Submitted: 2007-02-22
• Study First Submitted QC: 2007-02-22
• Study First Posted: 2007-02-23
• Last Update Submitted: 2017-01-10
• Last Update Posted: 2017-01-11

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 10

Inclusion Criteria

• Be between the ages of 18 and 45 years of age
• Be in general good health with a history of methamphetamine (MA) abuse (but not dependence)
• If female and of child bearing potential, agrees to use birth control
• Be able to understand and provide written informed consent
• Have a body mass index between 18 and 30
• Have reported use of (MA) during the past three months without experiencing adverse consequence plus a life time MA or amphetamine use history of at least four occasions of use
• Have a negative drug test (barbiturates, benzodiazepines, amphetamines, opiates, cocaine, cannabinoids, ethanol) at screening and at the time of admission

Exclusion Criteria

• Please contact site for details

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Cardiovascular responses

Secondary Outcome Measures

Name	Time	Method
Subjective effects

Trial Locations

Locations (1)

Langley Porter Psychiatric Institute; 🇺🇸 San Francisco, California, United States